A Multicenter, Double-Masked Evaluation of the Safety and Effectiveness of Aceclidine + Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
Latest Information Update: 09 Sep 2024
Price :
$35 *
At a glance
- Drugs Acecainide (Primary) ; Aceclidine/brimonidine (Primary)
- Indications Presbyopia
- Focus Therapeutic Use
- Sponsors LENZ Therapeutics
- 10 Jan 2023 Status changed from recruiting to completed.
- 18 Oct 2022 Planned End Date changed from 1 Oct 2022 to 23 Nov 2022.
- 18 Oct 2022 Planned primary completion date changed from 1 Sep 2022 to 2 Nov 2022.